Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.
PTC acquired gene therapy ST-920 for Fabry from bankrupt Sangamo for $111M upfront plus $100M in FDA milestones, targeting 2027 launch. Gene therapies remain viable; the $2B+ market and ST-920's edge justify PTC's rare-disease bet with infrastructure synergies.
An article from
Dive Brief
Wall Street analysts view the deal as a risky, high-reward bet on a treatment that’s nearing a possible regulatory approval and could be superior to existing medications.
Published Aug. 13, 2026
A gene therapy Sangamo sold in a bankruptcy auction is delivered with the help of an adeno-associated virus.
PTC Therapeutics plans to acquire Sangamo’s ST-920 Fabry disease program for $111 million upfront, with FDA filing expected in Q4…
The bankrupt gene editing biotech Sangamo is set to sell chunks of its business to PTC Therapeutics and Eli Lilly for up to $264…
Sangamo files for Chapter 11 as Eli Lilly and Astellas step in to buy its valuable gene therapy and genome-editing assets.
Eli Lilly and Astellas will be the lead bidders at an auction for Sangamo assets. Elsewhere, an investor syndicate committed $230…
Sangamo Therapeutics files for bankruptcy after three decades, selling assets to Eli Lilly for $50M and Astellas for up to $50M,…
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA…
